Liver Injury/Regeneration News

The American College of Gastroenterology has released guidelines and recommendations for physicians and health care providers to diagnosis and manage idiosyncratic drug-induced liver injury.

Liver injuries in patients who received statins for hyperlipidemia were rare, with patients displaying wide clinical presentations and latencies to onset, according to data from a new study.

Members of the All-Party Parliamentary Hepatology Group have asked the National Health Service in the United Kingdom to show more concern about the rise of liver disease.

Use of methotrexate to treat children with inflammatory bowel disease should be monitored closely to guard against hepatotoxicity, a meta-analysis determined.

WASHINGTON — Liver injury attributable to the use of herbal and dietary supplements, particularly products marketed for bodybuilding, has increased in recent years, according to data presented at The Liver Meeting.

Learning of potential liver risk from heavier alcohol consumption resulted in behavioral changes among responders to a mailed invitation for liver fibrosis screening in a recent community feasibility study.

A drug with a dose of 100 mg or greater and high lipophilicity is significantly more likely to lead to drug-induced liver injury, according to a recent study.

Drug-induced liver injury, most often presenting as acute hepatocellular injury with autoimmune features, may be a class effect of tumor necrosis factor-alpha antagonists, according to a recent case and literature review.

The FDA has determined that tolvaptan should not be used for longer than 30 days or in patients with underlying liver disease because it may cause liver injury potentially leading to liver transplant or death, according to a drug safety communication.

The FDA today issued a warning regarding the potential for hyponatremia treatment Samsca to cause liver injury.